Stakeholders have had a lot to react to as the biopharmaceutical industry rolls out second quarter sales and earnings figures, with the announcement that Pfizer Inc. will be splitting off its Upjohn division to merge with Mylan NV fanning already high flames around business development. Likewise, the US Senate Finance Committee’s drug pricing bill has prompted analyst queries for reaction from most of the major players.
[Sidebar#SC125606]








